CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis within a group of patients, all of whom developed lung metastasis

Modern Pathology

Volumn 19, Issue 5, 2006, Pages 738-745

  Oda, Yoshinao ^a   Yamamoto, Hidetaka ^a   Tamiya, Sadafumi ^a   Matsuda, Shuichi ^a   Tanaka, Kazuhiro ^a   Yokoyama, Ryohei ^b   Iwamoto, Yukihide ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

CXCR4; Lung metastasis; Microvessel density; Osteosarcoma; VEGF

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; MONOCLONAL ANTIBODY KI 67; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; BREAST CANCER; CANCER INVASION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; MICROVASCULARIZATION; MICROVASCULATURE; MICROVESSEL DENSITY; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD; THORACOTOMY;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; RECEPTORS, CXCR4; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33646125873     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800587     Document Type: Article

References (25)

1. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastases. Nature 2001;410:50-56.
2. Scotton CJ, Wilson JL, Milliken D, et al. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001;61:4961-4965.
3. Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastases to bone. Cancer Res 2002;62:1832-1837.
4. Schrader AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signaling in kidney cancer. Br J Cancer 2002;86:1250-1256.
5. Shibuta K, Mori M, Shimoda K, et al. Regional expression of CXCL12/CXCR4 in liver and hepatocellular carcinoma and cell-cycle variation during in vitro differentiation. Jpn J Cancer Res 2002;93:789-797.
6. Delibasi CB, Okura M, Iida S, et al. Investigation of CXCR4 in squamous cell carcinoma of the tongue. Oral Oncol 2004;40:154-157.
7. Fernandis AZ, Prasad A, Band H, et al. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004;23:157-167.
8. Russell HV, Hicks J, Okcu MF, et al. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg 2004;10:1506-1511.
9. Uchida D, Begum N-M, Tomizuka Y, et al. Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma. Lab Invest 2004;84:1538-1546.
10. Katayama A, Ogino T, Bandoh N, et al. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:2937-2946.
11. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor prognosis. J Clin Oncol 2005;23:2744-2753.
12. Retz MM, Sidhu SS, Blaveri E, et al. CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer 2005;114:182-189.
13. Wada T, Isu K, Takeda N, et al. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology 1996;53:221-227.
14. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23:559-568.
15. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 2005;11:490-497.
16. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-577.
17. Wang D, Chen L, Gao F. Correlation of tumor microvessel density with prognosis in osteogenic sarcoma. Chinese J Pathol 1997;26:266-269.
18. Kreuter M, Bieker R, Bielack SS, et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res 2004;10:8531-8537.
19. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 1999;35:1089-1093.
20. Kaya M, Wada T, Kawaguchi S, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002;86:864-869.
21. Oda Y, Naka T, Takeshita M, et al. Comparison of histologic changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma. A clinicopathologic and immunohistochemical study. Hum Pathol 2000;31:709-716.
22. Dorfman HD, Vanel D, Czerniak B, et al. WHO classification of tumours of bone: Introduction. In: Fletcher CDM, Unni KK, Mertens F (eds). WHO Classification of Tumours: Pathology and Genetics: Tumours of Soft Tissue and Bone. IARC Press: Lyon, 2002, pp 227-232.
23. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203-7206.
24. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
25. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989;86:7311-7315.